Full Breakdown
ImmunityBio Responds to FDA Concerns Over Promotional Materials
4/6/2026, 8:28:43 PM
Overview of the FDA Correspondence
ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company focused on immunotherapy, has submitted a comprehensive response to the U.S. Food and Drug Administration (FDA) regarding concerns raised about promotional materials for its lead biologic product, ANKTIVA® (nogapendekin alfa inbakicept-pmln). The FDA's Office of Prescription Drug Promotion (OPDP) issued a warning letter on March 13, 2026, citing misleading claims made by ImmunityBio's Executive Chairman, Dr. Patrick Soon-Shiong, during a podcast. The FDA determined that statements regarding ANKTIVA's capabilities, including claims that it "can cure and even prevent all cancer," were false or misleading.
Corrective Actions and Compliance Measures
In response to the FDA's concerns, ImmunityBio has initiated a thorough review of its promotional materials and is implementing enhanced compliance measures. These include the removal of the identified podcast from its corporate website and a request for its removal from third-party platforms. The company confirmed that the television advertisement referenced in the FDA correspondence was never aired. Richard Adcock, President and CEO of ImmunityBio, emphasized the company's commitment to promotional compliance, stating, “ImmunityBio takes promotional compliance with the utmost seriousness.”
Background on ANKTIVA®
ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The drug aims to activate natural killer (NK) cells and restore memory T cell activity, which is crucial for combating cancer. The IL-15 molecule, foundational to ANKTIVA, was characterized as a promising agent by the National Cancer Institute during its Immunotherapy Agent Workshop in 2007.
Legal Implications and Investor Concerns
Following the FDA's warning, ImmunityBio's stock price fell by 21.12%, closing at $7.42 per share on March 24, 2026. This decline prompted a securities fraud class action lawsuit against the company, alleging material misstatements and omissions regarding ANKTIVA. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, are encouraged to seek lead plaintiff status by May 26, 2026.
Criticism and Opposition
Critics of ImmunityBio have raised concerns regarding the accuracy of the company's promotional claims, particularly those made by Dr. Soon-Shiong. The lawsuit alleges that the company misrepresented ANKTIVA as a cancer vaccine and overstated its capabilities, leading to misleading statements about its business and operations.
Official Statements & Responses
ImmunityBio has reiterated its commitment to ensuring that all promotional communications for ANKTIVA are accurate and compliant with FDA regulations. The company is engaging external regulatory counsel to audit future communications and is enhancing its internal protocols to prevent similar issues in the future.
What's Next
ImmunityBio's ongoing efforts to address the FDA's concerns and the implications of the securities fraud lawsuit will be closely monitored by investors and regulatory bodies alike. The company's ability to navigate these challenges will be critical for its future operations and market performance.
